Exact incidence rates for every major Cialis (tadalafil) adverse event, drawn from FDA label data, key trials, FAERS reports, and post-market literature. Reviewed by HealthRX.com physicians.
A guide to rare but serious adverse events linked to Cialis (tadalafil), including NAION, priapism, Stevens-Johnson syndrome, and sudden hearing loss, with trial data, FAERS figures, and clinical thresholds.
Hair loss isn't among Farxiga's documented adverse events. See actual side effect rates, from genital infections (6-9%) to rare DKA and Fournier's gangrene.
A guide to delayed-onset side effects of dulaglutide (Trulicity), covering gastrointestinal, renal, thyroid, and rare adverse events with trial data, FAERS signals, and management protocols.
A clinical breakdown of dutasteride (Avodart) adverse events by frequency, severity grade, and patient phenotype, drawing on REDUCE, CombAT, key Phase III data, FDA labeling, and FAERS post-market surveillance.
Does stopping Avodart (dutasteride) cause withdrawal symptoms? Learn what the clinical evidence says about dutasteride discontinuation syndrome, DHT rebound, hair loss, and sexual side effects that persist after stopping.
A careful look at what the enclomiphene citrate safety literature does and does not establish, with the regulatory background, mechanistic reasoning, and an evidence-verification framework for readers evaluating incidence claims.
A guide to delayed-onset adverse events from estradiol transdermal patches, including VTE risk, endometrial changes, breast density, and skin reactions that appear weeks to months after starting HRT.
A clinically detailed guide to rare but serious adverse events associated with the estradiol transdermal patch, including VTE, stroke, breast cancer risk, and more. prepared by the HealthRX.com Editorial Team.
A guide to Repatha (evolocumab) side effects, including rare, serious, and potentially long-lasting adverse events, with data from FOURIER, FAERS, and the FDA prescribing label.
Most finasteride side effects fade after stopping, but some men report lasting sexual and mood changes, per FDA and FAERS data. See what's documented.
A breakdown of finasteride adverse events by severity and patient phenotype, drawing on PCPT trial data, FDA FAERS reports, and post-market literature to help patients and prescribers understand real-world risk.
A clinical deep-dive into flibanserin (Addyi) delayed-onset side effects, including dizziness, hypotension, CNS depression, and rare FAERS-reported reactions, with prescribing guidance and monitoring tips.
A breakdown of flibanserin (Addyi) adverse event rates from phase III trials, FDA review documents, FAERS data, and post-market literature, with exact percentages, named studies, and clinical guidance.
A clinical deep-dive into the rare but serious adverse events associated with flibanserin (Addyi), including syncope, CNS depression, and hypotension, with data from FDA labeling, FAERS, and post-market surveillance.
A guide to flibanserin (Addyi) withdrawal and discontinuation syndrome, covering mechanism, documented adverse events, FAERS data, clinical trial findings, and how to stop safely.
Injection-site reactions were most common (8.2% vs 1.8% placebo) across ORION-9/10/11. No significant liver, kidney, or muscle toxicity signals emerged.
Most Leqvio side effects are mild injection-site reactions (8.2% vs 1.8% placebo); permanent effects remain unconfirmed in trial data. See what to monitor.
A guide to the rare but serious adverse events linked to Leqvio (inclisiran), covering trial data, FDA labeling, post-market reports, and how to monitor patients on twice-yearly PCSK9i injections.
A guide to delayed-onset side effects of ipamorelin acetate, covering GH axis desensitization, fluid retention, cortisol changes, injection-site reactions, and what post-market data show.
A data-driven review of ipamorelin adverse events, incidence rates from clinical trials, FAERS reports, and post-market literature, prepared by the HealthRX.com Editorial Team.
A guide to rare but serious adverse events associated with ipamorelin, including cardiovascular, oncologic, endocrine, and injection-site risks, with citations to clinical trials and FAERS data.
A clinical breakdown of ipamorelin adverse events by severity grade and patient phenotype, including data from FAERS, post-market literature, and HealthRX.com cohort observations. prepared by the HealthRX.com Editorial Team.
A comprehensive review of liraglutide adverse event rates drawn from SCALE, LEADER, and LIRA-PCOS trials, FDA labeling, and post-market FAERS data, with exact incidence figures, head-to-head comparisons, and clinical management guidance.
A clinical deep-dive into how liraglutide adverse events vary by patient phenotype, covering GI toxicity, pancreatitis risk, cardiac effects, and rare reactions with trial data, FAERS analysis, and dosing guidance.
Stopping lisinopril doesn't cause classic withdrawal, but blood pressure can rebound within 24 to 72 hours; ACE cough typically clears in 1 to 4 weeks.
A comprehensive, citation-dense review of low-dose naltrexone (LDN) adverse events and incidence rates drawn from randomized trials, FAERS data, and post-market literature.
A guide to MK-677 (ibutamoren) adverse events, withdrawal symptoms after stopping, and how to manage discontinuation safely, with primary-source citations throughout.
MOTS-c does not have a human adverse-event profile yet. Separate observed events from theoretical biology, product-quality risks, and missing evidence.
A detailed breakdown of tirzepatide (Mounjaro) adverse event rates from SURPASS trials, FDA label data, FAERS reports, and post-market literature, with exact percentages and clinical context.
A guide to Mounjaro (tirzepatide) side effects, including rare adverse events that may be long-lasting or permanent, with citations from clinical trials, FDA labeling, and post-market surveillance.
A clinical review of delayed-onset side effects from NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) supplementation, including nausea, sleep disruption, methylation burden, and cancer-related signals. Evidence from human trials, FAERS reports, and post-market literature.
A clinical review of rare but serious adverse events linked to NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside), including hepatotoxicity signals, methylation burden, oncology concerns, and what human trial data actually shows.
A guide to oral micronized progesterone (Prometrium) side effects, including rare but potentially permanent adverse events, drawn from clinical trials, FDA labeling, and post-market surveillance data.
A comprehensive clinical review of rare but serious adverse events associated with oral micronized progesterone (Prometrium), including thromboembolism, hepatotoxicity, anaphylaxis, and cardiovascular risks. Backed by trial data, FDA labeling, and post-market surveillance.
A comprehensive, citation-dense review of oral minoxidil adverse event rates drawn from randomized trials, FAERS reports, the FDA label, and post-market literature. Updated for clinicians and patients.
A guide to PT-141 (bremelanotide) adverse events, what happens when you stop the drug, whether a true withdrawal syndrome exists, and how to manage discontinuation safely.
A clinical breakdown of Rybelsus (oral semaglutide) adverse event rates from PIONEER trials, FDA labeling, and post-market data, with exact incidence figures and management guidance.
A data-driven breakdown of spironolactone adverse events by frequency, drawn from randomized trials, the FDA label, FAERS reports, and post-market literature. prepared by the HealthRX.com Editorial Team.
A clinical deep-dive into suvorexant withdrawal, rebound insomnia, and discontinuation symptoms, with trial data, FDA label guidance, and protocols.
A clinical deep-dive into tadalafil withdrawal and discontinuation effects, covering rebound phenomena, symptom timelines, FAERS data, and evidence-based management strategies for patients stopping generic tadalafil 2.5 to 20 mg.
A clinical breakdown of tesamorelin adverse events by severity grade and patient phenotype, drawing on Phase 3 trial data, FDA labeling, FAERS reports, and post-market literature.
A guide to tesamorelin withdrawal and discontinuation effects, covering visceral fat rebound, IGF-1 normalization, glucose changes, and how to taper or stop Egrifta safely.
A clinically detailed guide to the delayed-onset side effects of testosterone cypionate, including polycythemia, cardiovascular changes, testicular atrophy, and more. prepared by the HealthRX.com Editorial Team.
A clinical deep-dive into the rare but serious adverse events associated with testosterone cypionate, including cardiovascular risk, polycythemia, hepatotoxicity, and more. prepared by the HealthRX.com Editorial Team.
A guide to the rare but serious adverse events linked to Testosterone Enanthate, including polycythemia, cardiovascular risk, hepatotoxicity, and more. Backed by trials, FDA labeling, and post-market data.
A comprehensive clinical breakdown of thymosin alpha-1 (thymalfasin) adverse events, organized by severity grade and patient phenotype, with citations from trials, FAERS data, and post-market literature.
A breakdown of tretinoin adverse events by skin type, age, and comorbidity. Includes trial data, FAERS analysis, and a phenotype-matched severity framework.
A comprehensive clinical guide to delayed-onset and rare adverse events from Viagra (sildenafil), including NAION, hearing loss, priapism, and skin reactions, with trial data, FAERS reports, and FDA label citations.
A guide to delayed-onset Wegovy (semaglutide 2.4 mg) side effects, including gallbladder disease, pancreatitis, kidney injury, hair loss, and psychiatric changes that typically appear weeks to months into therapy.
A data-driven breakdown of Wegovy (semaglutide 2.4 mg) side effect incidence rates from STEP trials, FDA labeling, FAERS reports, and post-market literature.
A clinical breakdown of Wegovy (semaglutide 2.4 mg) adverse events by severity and patient phenotype, citing STEP trials, FDA labeling, and FAERS post-market data to help clinicians and patients understand who is most at risk.
A complete breakdown of Zepbound (tirzepatide) adverse event rates from SURMOUNT-1 through SURMOUNT-4, the FDA label, FAERS post-market reports, and head-to-head comparator data.
A comprehensive clinical breakdown of Zepbound (tirzepatide) adverse events by severity grade and patient phenotype, drawing on SURMOUNT trial data, FDA labeling, and FAERS post-market reports.
Wegovy slows gut transit and causes constipation in roughly 24% of users. This evidence-based guide covers why it happens, how long it lasts, and which supplements have the strongest clinical support for relief.
A clinically detailed, week-by-week breakdown of diarrhea during Wegovy therapy, covering onset, peak, resolution, and the STEP trial data behind each phase, plus actionable management steps.
Persistent diarrhea on Wegovy (semaglutide 2.4 mg) explained: why it happens, what the trial data show, how to manage it, and when to call your prescriber.
Learn why Wegovy causes nausea, how long it lasts, and which evidence-based diet protocols reduce nausea during semaglutide 2.4 mg treatment. Reviewed by board-certified physicians.
A safety guide to generic sildenafil (20 to 100 mg) for adults aged 30, 49, covering contraindications, drug interactions, cardiovascular risk, side effects, and dosing protocols with primary-source citations.
A guide to sildenafil safety in patients 65 and older, covering starting doses, drug interactions, fall risk, renal and hepatic adjustments, and when to avoid the drug entirely.